{"id":441755,"date":"2021-02-23T08:03:28","date_gmt":"2021-02-23T13:03:28","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=441755"},"modified":"2021-02-23T08:03:28","modified_gmt":"2021-02-23T13:03:28","slug":"jounce-therapeutics-to-present-at-upcoming-investor-conferences-in-march","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/jounce-therapeutics-to-present-at-upcoming-investor-conferences-in-march\/","title":{"rendered":"Jounce Therapeutics to Present at Upcoming Investor Conferences in March"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">CAMBRIDGE, Mass., Feb.  23, 2021  (GLOBE NEWSWIRE) &#8212; Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Jounce management will present at several upcoming investor conferences:<\/p>\n<ul type=\"disc\">\n<li style=\"text-align:left\">\n          <strong>Cowen &amp; Co. 41<\/strong><br \/>\n          <sup><br \/>\n            <strong>st<\/strong><br \/>\n          <\/sup><br \/>\n          <strong> Annual Health Care Conference: <\/strong>A panel discussion will be available live to conference attendees on Monday, March 1, 2021 at 10:30 a.m. ET.<\/li>\n<li>\n          <strong>42<\/strong><br \/>\n          <sup><br \/>\n            <strong>nd<\/strong><br \/>\n          <\/sup><br \/>\n          <strong> Annual Raymond James Institutional Investors Conference: <\/strong>A live webcast fireside chat will take place on Tuesday, March 2, 2021 at 3:50 p.m. ET.<\/li>\n<li>\n          <strong>H.C. Wainwright Global Life Sciences Conference:<\/strong> A webcast presentation will be available on demand during the conference, starting Tuesday, March 9, 2021 at 7:00 a.m. ET.<\/li>\n<li>\n          <strong>33<\/strong><br \/>\n          <sup><br \/>\n            <strong>rd<\/strong><br \/>\n          <\/sup><br \/>\n          <strong> Annual ROTH Conference: <\/strong>A live webcast panel discussion will take place on Monday, March 15, 2021 at 2:00 p.m. ET.<\/li>\n<\/ul>\n<p>Presentation webcasts will be available by visiting \u201cEvents and Presentations\u201d in the Investors and Media section of Jounce\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vnzGJipybcGF3X_pIoVqjQs5LEfxFMx6mUlL8UIlmthS6Z4O1MWozgYOD2GHPKTQL6bNZcPn4Jl-z8xuO-8QBQ==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.jouncetx.com<\/a>. The webcasts will be archived for 30 days following the presentations.<\/p>\n<p>\n        <strong>About Jounce Therapeutics<\/strong><br \/>\n        <br \/>Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce\u2019s highest priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state in preclinical studies. A Phase 1 clinical trial, named INNATE, for JTX-8064 as a monotherapy and in combination with JTX-4014, Jounce\u2019s internal PD-1 inhibitor, or pembrolizumab is currently enrolling patients with advanced solid tumors. Jounce\u2019s most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the SELECT Phase 2 trial. JTX-4014 is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounce\u2019s broader pipeline. Additionally, Jounce exclusively licensed worldwide rights to JTX-1811, a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc. For more information, please visit <u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vnzGJipybcGF3X_pIoVqjTRRgVUDtMDuGaoHJHW5RVSNUSGBHewzDiV18jx9BB4PXOwzoeWgUF3wdGoNR7yGWg==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.jouncetx.com<\/a><\/u>.<\/p>\n<p>\n        <strong>Investor and Media Contacts:<\/strong><br \/>\n        <br \/>Malin Deon<br \/>Jounce Therapeutics, Inc.<br \/>+1-857-259-3843<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VV_JxFSqWa1Ns4MVh4qwiE5IqOvvmuCbJN3FhWvJvYKfQ7df0HtX2vriLdLEaJCn3TTn8gHtTFXYhKJeSafECjItD_0KXDY-PzR0F7YkDJk=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">mdeon@jouncetx.com<\/a><\/p>\n<p>Mark Yore<br \/>Jounce Therapeutics, Inc.<br \/>+1-857-200-1255 <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=P6r74IqR26K3wTCIsWJjKokGWPycxkbEw4VqXzz-obqxVGjh79JbL6zo-H2lXi6E9jqU1PAs4_xfWirsrowY4tbnafaISMWm63YxzZTNjTQ=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">myore@jouncetx.com<\/a><\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NzUxNCMzOTg5Mzk3IzIwMjYxMzk=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/9517f606-e00d-4288-a269-c328adf033ec\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass., Feb. 23, 2021 (GLOBE NEWSWIRE) &#8212; Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Jounce management will present at several upcoming investor conferences: Cowen &amp; Co. 41 st Annual Health Care Conference: A panel discussion will be available live to conference attendees on Monday, March 1, 2021 at 10:30 a.m. ET. 42 nd Annual Raymond James Institutional Investors Conference: A live webcast fireside chat will take place on Tuesday, March 2, 2021 at 3:50 p.m. ET. H.C. Wainwright Global Life Sciences Conference: A webcast presentation will be available on demand during the conference, starting Tuesday, March 9, 2021 at 7:00 a.m. ET. &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/jounce-therapeutics-to-present-at-upcoming-investor-conferences-in-march\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Jounce Therapeutics to Present at Upcoming Investor Conferences in March&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-441755","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Jounce Therapeutics to Present at Upcoming Investor Conferences in March - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/jounce-therapeutics-to-present-at-upcoming-investor-conferences-in-march\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Jounce Therapeutics to Present at Upcoming Investor Conferences in March - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass., Feb. 23, 2021 (GLOBE NEWSWIRE) &#8212; Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Jounce management will present at several upcoming investor conferences: Cowen &amp; Co. 41 st Annual Health Care Conference: A panel discussion will be available live to conference attendees on Monday, March 1, 2021 at 10:30 a.m. ET. 42 nd Annual Raymond James Institutional Investors Conference: A live webcast fireside chat will take place on Tuesday, March 2, 2021 at 3:50 p.m. ET. H.C. Wainwright Global Life Sciences Conference: A webcast presentation will be available on demand during the conference, starting Tuesday, March 9, 2021 at 7:00 a.m. ET. &hellip; Continue reading &quot;Jounce Therapeutics to Present at Upcoming Investor Conferences in March&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/jounce-therapeutics-to-present-at-upcoming-investor-conferences-in-march\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-02-23T13:03:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NzUxNCMzOTg5Mzk3IzIwMjYxMzk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jounce-therapeutics-to-present-at-upcoming-investor-conferences-in-march\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jounce-therapeutics-to-present-at-upcoming-investor-conferences-in-march\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Jounce Therapeutics to Present at Upcoming Investor Conferences in March\",\"datePublished\":\"2021-02-23T13:03:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jounce-therapeutics-to-present-at-upcoming-investor-conferences-in-march\\\/\"},\"wordCount\":404,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jounce-therapeutics-to-present-at-upcoming-investor-conferences-in-march\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE1NzUxNCMzOTg5Mzk3IzIwMjYxMzk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jounce-therapeutics-to-present-at-upcoming-investor-conferences-in-march\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jounce-therapeutics-to-present-at-upcoming-investor-conferences-in-march\\\/\",\"name\":\"Jounce Therapeutics to Present at Upcoming Investor Conferences in March - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jounce-therapeutics-to-present-at-upcoming-investor-conferences-in-march\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jounce-therapeutics-to-present-at-upcoming-investor-conferences-in-march\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE1NzUxNCMzOTg5Mzk3IzIwMjYxMzk=\",\"datePublished\":\"2021-02-23T13:03:28+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jounce-therapeutics-to-present-at-upcoming-investor-conferences-in-march\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jounce-therapeutics-to-present-at-upcoming-investor-conferences-in-march\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jounce-therapeutics-to-present-at-upcoming-investor-conferences-in-march\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE1NzUxNCMzOTg5Mzk3IzIwMjYxMzk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE1NzUxNCMzOTg5Mzk3IzIwMjYxMzk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jounce-therapeutics-to-present-at-upcoming-investor-conferences-in-march\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Jounce Therapeutics to Present at Upcoming Investor Conferences in March\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Jounce Therapeutics to Present at Upcoming Investor Conferences in March - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/jounce-therapeutics-to-present-at-upcoming-investor-conferences-in-march\/","og_locale":"en_US","og_type":"article","og_title":"Jounce Therapeutics to Present at Upcoming Investor Conferences in March - Market Newsdesk","og_description":"CAMBRIDGE, Mass., Feb. 23, 2021 (GLOBE NEWSWIRE) &#8212; Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Jounce management will present at several upcoming investor conferences: Cowen &amp; Co. 41 st Annual Health Care Conference: A panel discussion will be available live to conference attendees on Monday, March 1, 2021 at 10:30 a.m. ET. 42 nd Annual Raymond James Institutional Investors Conference: A live webcast fireside chat will take place on Tuesday, March 2, 2021 at 3:50 p.m. ET. H.C. Wainwright Global Life Sciences Conference: A webcast presentation will be available on demand during the conference, starting Tuesday, March 9, 2021 at 7:00 a.m. ET. &hellip; Continue reading \"Jounce Therapeutics to Present at Upcoming Investor Conferences in March\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/jounce-therapeutics-to-present-at-upcoming-investor-conferences-in-march\/","og_site_name":"Market Newsdesk","article_published_time":"2021-02-23T13:03:28+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NzUxNCMzOTg5Mzk3IzIwMjYxMzk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/jounce-therapeutics-to-present-at-upcoming-investor-conferences-in-march\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/jounce-therapeutics-to-present-at-upcoming-investor-conferences-in-march\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Jounce Therapeutics to Present at Upcoming Investor Conferences in March","datePublished":"2021-02-23T13:03:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/jounce-therapeutics-to-present-at-upcoming-investor-conferences-in-march\/"},"wordCount":404,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/jounce-therapeutics-to-present-at-upcoming-investor-conferences-in-march\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NzUxNCMzOTg5Mzk3IzIwMjYxMzk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/jounce-therapeutics-to-present-at-upcoming-investor-conferences-in-march\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/jounce-therapeutics-to-present-at-upcoming-investor-conferences-in-march\/","name":"Jounce Therapeutics to Present at Upcoming Investor Conferences in March - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/jounce-therapeutics-to-present-at-upcoming-investor-conferences-in-march\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/jounce-therapeutics-to-present-at-upcoming-investor-conferences-in-march\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NzUxNCMzOTg5Mzk3IzIwMjYxMzk=","datePublished":"2021-02-23T13:03:28+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/jounce-therapeutics-to-present-at-upcoming-investor-conferences-in-march\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/jounce-therapeutics-to-present-at-upcoming-investor-conferences-in-march\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/jounce-therapeutics-to-present-at-upcoming-investor-conferences-in-march\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NzUxNCMzOTg5Mzk3IzIwMjYxMzk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NzUxNCMzOTg5Mzk3IzIwMjYxMzk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/jounce-therapeutics-to-present-at-upcoming-investor-conferences-in-march\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Jounce Therapeutics to Present at Upcoming Investor Conferences in March"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/441755","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=441755"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/441755\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=441755"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=441755"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=441755"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}